For many years, a team of researchers at the University of Copenhagen have been focusing on developing a vaccine that can protect against pregancy malaria from which 220,000 people die every year.
Now they have come a significant step closer to being able to introduce such a vaccine in the market. In a new study published in the scientific journal Clinical Infectious Diseases the vaccine has been subjected to so-called phase one clinical trial, and the results are uplifting: The vaccine is safe to use, and it passes the test by inducing the right antibody response in the blood.
"It is a great milestone for us to be able to show that our vaccine is completely safe and induces the exact antibody response in the blood we want. Because it is the immune response that has been shown to be connected with protection from pregnancy malaria. The next step is to document that it prevents pregnancy malaria in African women who would otherwise have contracted the disease," says lead author and associate professor Morten Agertoug Nielsen from the Department of Immunology and Microbiology.
The researchers have applied the normal method for testing new drugs by doing a so-called randomized, double-blind study. This means that the test subjects were randomly given the vaccine and placebo, respectively, and neither the subjects nor the researchers performing the study knew who got what.
The effect of the vaccine was examined among 36 German women and men who had volunteered for the trial. After injecting the test subjects with the vaccine, the researchers were able to detect the right immune response with antibodies against the malaria parasite in the blood, and the subjects showed no serious side effects.
The German test subjects are described as 'malaria naïve', because they are not and will not be exposed to the malaria parasite and therefore will never develop pregnancy malaria. They were nevertheless used as test subjects to document that the vaccine is safe and appears to work, before it is introduced in a group of African women vulnerable and at risk of developing pregnancy malaria.
"Of course, we will be doing more tests, because we want to take the vaccine as far as we can. We are therefore cooperating with hospitals in Benin in Africa, where we can conduct studies in women in risk of developing the disease. We expect to be able to publish the results of these studies sometime next year," says co-author of the study, professor Ali Salanti from the Department of Immunology and Microbiology.
The researchers' journey towards a malaria vaccine began with Ali Salanti's discovery of the protein hook in the placenta of pregnant women to which the malaria parasite may attach itself. Subsequently, Ali Salanti and his research team have been trying to utilise this knowledge to produce an actual vaccine against the fatal disease.
"Our development and production of the vaccine has only been possible due to our close public-private collaborations. It is a strong example of how such a constellation can make it possible to develop medicine for people in need, including people with few resources," says Salanti.
In academia, it is also unusual to see researchers take their discovery further to clinical trials. Clinical trials can be extensive and expensive, and therefore the pharmaceutical industry is typically the one developing and safety-testing drugs before introducing them in the market. But in this case the researchers have managed to do so themselves.
"The next step in the process is a phase two clinical trial, which will show whether the vaccine is still safe, but also whether it can prevent disease. Concurrently, we have developed a method for transforming the vaccine into a virus-like particle. This increases the antibody response. But the crux of the matter is whether it is sufficient for attacking all the different forms of the protein hook found in the malaria parasite," says Nielsen.
The University of Copenhagen owns the patent on the vaccine technology, but the researchers have also cooperated with a series of companies on realising the malaria vaccine. Among other things, the researchers have founded the spinout NextGen Vaccines Aps, which together with the private biotech company ExpreS2ion Biotechnologies Aps has formed the joint venture company AdaptVac Aps. They all work together on developing this type of vaccine. In addition, the researchers have cooperated with AGC Biologics (previously called CMC Biologics), who has been responsible for producing the active substance in the vaccine.
In this study, the researchers have also worked closely together with researchers at Tübingen University Hospital and the German Center for Infection Research.
The study is funded by the EU programme FP7-Health-2012-Innovation, the Danish National Advanced Technology Foundation, the Independent Research Fund Denmark, the German Federal Ministry of Education and Research the Bill & Melinda Gates Foundation.
Source: University of Copenhagen